Paper42292467
Study of JCAD for prognosis and immune infiltration in hepatocellular carcinoma.
Wang Z and 8 others. Front Immunol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Study of JCAD for prognosis and immune infiltration in hepatocellular carcinoma. Papers, record 42292467. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42292467
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Biomarkers, Tumor | Major topic |
| Lymphocytes, Tumor-Infiltrating | Major topic |
| Humans | |
| Prognosis | |
| Female | |
| Male | |
| Gene Expression Regulation, Neoplastic | |
| Tumor Microenvironment | |
| Computational Biology |
Source PubMed
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40682115 | SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40682115 | PubMed |
| 2 | 40702000 | RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40702000 | PubMed |
| 3 | 38086932 | Therapeutic induction of antigen-specific immune tolerance. | Nat Rev Immunol | 2024 | https://conductscience.org/library/papers/38086932 | PubMed |
| 4 | 39950116 | Deciphering the heterogeneity and plasticity of the tumor microenvironment in liver cancer provides insights for prognosis. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/39950116 | PubMed |
| 5 | 39692577 | Down-regulation of JCAD Expression Attenuates Cardiomyocyte Injury by Regulating the Wnt/β-Catenin Pathway. | Folia Biol (Praha) | 2024 | https://conductscience.org/library/papers/39692577 | PubMed |
| 6 | 33237311 | The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. | Nucleic Acids Res | 2021 | https://conductscience.org/library/papers/33237311 | PubMed |
| 7 | 28775168 | JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity. | Cancer Res | 2017 | https://conductscience.org/library/papers/28775168 | PubMed |
| 8 | 38898190 | Higher inflammatory response in hepatocellular carcinoma is associated with immune cell infiltration and a better outcome. | Hepatol Int | 2024 | https://conductscience.org/library/papers/38898190 | PubMed |
| 9 | 38509842 | JCAD deficiency delayed liver regenerative repair through the Hippo-YAP signalling pathway. | Clin Transl Med | 2024 | https://conductscience.org/library/papers/38509842 | PubMed |
| 10 | 29092952 | TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. | Cancer Res | 2017 | https://conductscience.org/library/papers/29092952 | PubMed |
| 11 | 36727075 | Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. | Front Oncol | 2022 | https://conductscience.org/library/papers/36727075 | PubMed |
| 12 | 36181081 | Characterizing inflammatory markers in highly aggressive soft tissue sarcomas. | Medicine (Baltimore) | 2022 | https://conductscience.org/library/papers/36181081 | PubMed |
| 13 | 38350421 | Precision treatment in advanced hepatocellular carcinoma. | Cancer Cell | 2024 | https://conductscience.org/library/papers/38350421 | PubMed |
| 14 | 38742112 | Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification. | Front Immunol | 2024 | https://conductscience.org/library/papers/38742112 | PubMed |
| 15 | 39988347 | Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/39988347 | PubMed |
| 16 | 40812667 | Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma. | J Hepatol | 2026 | https://conductscience.org/library/papers/40812667 | PubMed |
| 17 | 37492708 | Application and progress of the detection technologies in hepatocellular carcinoma. | Genes Dis | 2023 | https://conductscience.org/library/papers/37492708 | PubMed |
| 18 | 33510460 | Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. | Nat Rev Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/33510460 | PubMed |
| 19 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 20 | 38162657 | The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy. | Front Immunol | 2023 | https://conductscience.org/library/papers/38162657 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42292467
GET https://conductscience.org/api/papers/v1/42292467/references?page=2